Health
Bayer Pharma Head Sees Brighter Future With Deals, New Drugs
- Oelrich aims to do deals in the €1 billion to €5 billion range
- New gene therapies are also starting to show promise in trials
The Bayer AG pharmaceutical campus in Berlin, Germany.
Photographer: Krisztian Bocsi/BloombergThis article is for subscribers only.
Bayer AG is considering doing deals in the range of €1 billion to €5 billion ($1.1 billion to $5.5 billion) as the drugmaker seeks to rebuild its pipeline of new medicines.
Top drugs are losing exclusivity and a promising experimental candidate recently failed. But Bayer’s pharma head, Stefan Oelrich, said Monday that the company has built up a portfolio of earlier-stage assets that show a lot of promise, and he’s also open to licensing deals for existing drugs.